The SMC Group and EMCVPA Partner to Boost Jamaica’s Creative Industries
30.6.2021 17:00:00 EEST | Business Wire | Press release
Jamaica’s creative sector has received a major boost through a partnership between global entertainment marketing agency, The SMC Group, and The Edna Manley College of the Visual and Performing Arts (EMCVPA). This arrangement aims to foster the development of Jamaican talent and the island’s Creative Industries.
The venture will begin with an investment into the development of a music production studio to support local song writers, producers, and artistes. SMC also intends to recruit EMCVPA students for apprenticeships and job placements. This ground-breaking initiative will enhance the music and audio production, animation, as well as dance specialisations at the College.
The partnership is the latest positive development in the island’s creative industries which have seen considerable growth in recent years.
In the film industry, more than 4000 film-related jobs have been created in the last three years while approximately 150 foreign productions are facilitated per year. Over 3 billion JMD in film production expenditure was contributed to GDP in the last two years, and approximately 65-70 percent of crews hired on most international film productions in Jamaica are local.
The country also has a growing animation industry with 15 local studios having participated in government-led programmes to increase their profitability and sustainability.
CEO of The SMC Group, Maurice Hamilton, revealed that the collaboration between the group and EMCVPA will add to the progress that has already been made in the creative industries by expanding investment into the areas of talent and content in the music and audio-visual sectors.
“This is the first step of an exciting initiative to establish Jamaica and then the wider Caribbean region as a creative hub that will develop creative and business professionals as well as content,” the CEO remarked. “And for SMC, it creates a solid, efficient pipeline of creative talent to service our global clients.”
The CEO also disclosed that SMC intends to build a centre of excellence in Jamaica and will be engaging in additional investments and local partnerships.
“We want to ensure that our commitment to Jamaican talent is substantive,” he insisted. “Through greater education, funding, and through our network within the global marketplace we can provide a platform from which Jamaican talent can flourish internationally.”
The island has seen several ventures over the years led by the private sector, public sector or both, which seek to advance the creative industry. Programmes such as the Business of Sustainability for Studios (BOSS) programme, JAFTA Propella film development programme, and the Film Lab initiative help entrepreneurs grow their animation and film production studios, and increase content development.
In the spirit of these collaborations between industry stakeholders, Diane Edwards, President of Jamaica’s investment and export promotions agency, JAMPRO, welcomed the cooperation between SMC and EMCVPA.
“At JAMPRO, we believe that partnership is essential to building local industries and to creating valuable opportunities for Jamaica’s people, so we are pleased to see this agreement between SMC and Edna Manley College,” she said.
EMCVPA’s Vice Principal of Administration and Resource Development, Ms. Kerry Ann Henry, shared her enthusiasm for the partnership and explained that its objectives were in keeping with the college’s mission. She stated, “This is a partnership that will not just strengthen our respective organizations, it will be of enormous benefit to the country in fields related to the visual and performing arts.”
About The SMC Group
The SMC Group operates in 17 markets across the globe and has worked on campaigns for brands like The Coca-Cola Company, Net-A-Porter, Unilever, Diageo, Cartier and a host of globally recognizable names. Their projects have also involved celebrities like Jamaican Olympian Usain Bolt, Korean pop band BTS, Colombian superstar Maluma and American celebrities such as Kevin Hart, Jason Derulo and Kanye West.
ABOUT JAMPRO
The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.
For more information on JAMPRO, please visit https://dobusinessjamaica.com/.
Follow us on:
Twitter
Facebook
Instagram
LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005271/en/
Contact information
Integrated Marketing Communications
Tamica Parchment
tparchment@jamprocorp.com
Tele: 876-978-7755
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
